Trouble logging in? Forgot password? We can help!
215-685-6784
215-238-6944
Fill out both forms, then either email or fax them to us at the contact above.
Provider? Stay in the know
Get the newest information from the Immunization Program right in your inbox!
Sign upCOVID-19 Vaccine Available to Order Through VFC and the Bridge Access Program On September 12, 2023, ACIP approved the use of updated COVID-19 vaccines. The new products are monovalent (single), Omicron variant XBB.1.5. Under the new recommendation, everyone over 6 months is eligible for an updated...
Pediatric Pneumococcal Vaccine Updates As a reminder, Prevnar 20 (PCV20, Pneumococcal 20-valent Conjugant Vaccine; NDC 00005-2000-10) is now available to order for your VFC eligible patients. Prevnar 13 (PCV13) is no longer available to order through the VFC program. Please read our previous advisory on these changes. To transition...
COVID-19 Program Ends Today Today, Tuesday, September 12, 2023, marks the end of PDPH's COVID-19 program and the beginning of commercialization. Bivalent COVID-19 vaccines are no longer be authorized for use. Any remaining products in your inventory must be immediately discarded. Use of unauthorized product to vaccinate patients is not...
New Vaccine Product Available for VFC/VFAAR A one-vial presentation of Menveo (MenACYW-135) is now available through the Philadelphia VFC & VFAAR programs. This presentation does not require reconstitution. The Prescribing Information now describes both presentations of Menveo: the current two-vial presentation and a new one-vial presentation. One-vial Presentation (NEW) NDC: 58160-0827-30 For use in individuals 10 years through...
Urgent Update on COVID-19 Program The Philadelphia Department of Public Health's (PDPH) COVID-19 program is expected to end this Tuesday, 9/12 when full commercialization begins. Any COVID-19 vaccine in your inventory received from PDPH will no longer be authorized for use. All remaining inventory must be reported as wastage and...
Private COVID-19 Vaccine Procurement Commercialization of COVID-19 vaccines is occurring next week. VFC Providers are required to match vaccines on the private side. We have created an FAQ to assist providers through this transition. Take these steps now to plan which COVID-19 vaccines you will purchase privately: Review the anticipated...
[vc_row][vc_column][vc_column_text] New Vaccine Product Available Through VFC: Prevnar 20 On June 27, 2023, the CDC approved Prevnar 20 (PCV20) for use in pediatric patients. Beginning September 6, 2023, this Prevnar 20 is available to order for your VFC eligible patients. The Prevnar 13 (PCV13) is no longer...
Recap: RSV Immunization in Outpatient Settings Thank you to those who attended the RSV townhall for nirsevimab (Beyfortus) immunization in outpatient settings on Tuesday, August 29! In case you missed it, please review important information below: PDPH townhall presentation slides PDPH townhall meeting recording Nirsevimab FAQ Nirsevimab planning checklist Nirsevimab will...
Integrating RSV Immunization into EHR Systems RSV immunization will be available to order through the Vaccines for Children (VFC) program this fall. This newly approved monoclonal antibody, nirsevimab (Beyfortus), will be used to protect newborns and infants born during or entering their first RSV season.As your facility will likely...
Recap: RSV Immunization in Inpatient Settings Thank you to those who attended the RSV townhall for nirsevimab (Beyfortus) immunization in inpatient settings on Friday, August 24! In case you missed it, please review important information below: PDPH townhall presentation slides PDPH townhall meeting recording Nirsevimab FAQ Nirsevimab planning checklist Nirsevimab will...
